- Home
- CVKD vs LGVN Comparison
CVKD vs LGVN Comparison
Compare CVKD & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- LGVN
- Stock Information
- Founded
- CVKD 2022
- LGVN 2014
- Country
- CVKD United States
- LGVN United States
- Employees
- CVKD N/A
- LGVN N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CVKD Health Care
- LGVN Health Care
- Exchange
- CVKD Nasdaq
- LGVN Nasdaq
- Market Cap
- CVKD 29.5M
- LGVN 16.4M
- IPO Year
- CVKD 2023
- LGVN 2021
- Fundamental
- Price
- CVKD $12.64
- LGVN $0.75
- Analyst Decision
- CVKD Strong Buy
- LGVN Strong Buy
- Analyst Count
- CVKD 1
- LGVN 2
- Target Price
- CVKD $32.00
- LGVN $6.50
- AVG Volume (30 Days)
- CVKD 24.4K
- LGVN 416.4K
- Earning Date
- CVKD 11-06-2025
- LGVN 11-11-2025
- Dividend Yield
- CVKD N/A
- LGVN N/A
- EPS Growth
- CVKD N/A
- LGVN N/A
- EPS
- CVKD N/A
- LGVN N/A
- Revenue
- CVKD N/A
- LGVN $2,073,000.00
- Revenue This Year
- CVKD N/A
- LGVN N/A
- Revenue Next Year
- CVKD N/A
- LGVN N/A
- P/E Ratio
- CVKD N/A
- LGVN N/A
- Revenue Growth
- CVKD N/A
- LGVN 68.67
- 52 Week Low
- CVKD $8.74
- LGVN $0.63
- 52 Week High
- CVKD $22.90
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- CVKD 48.59
- LGVN 35.53
- Support Level
- CVKD $13.12
- LGVN $0.74
- Resistance Level
- CVKD $13.69
- LGVN $0.85
- Average True Range (ATR)
- CVKD 0.59
- LGVN 0.05
- MACD
- CVKD -0.06
- LGVN 0.02
- Stochastic Oscillator
- CVKD 21.08
- LGVN 21.23
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.